drugset / Trial / NCT05496569

TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

NCT05496569

Phase 2 Terminated 26 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

A clinical trial evaluating TQB3616 capsules versus placebo in the treatment of dedifferentiated liposarcoma. Divided into 2 stages, the second stage, a total of 118 subjects are planned to be enrolled.

Timeline

Start
2022-08-08
Primary completion
2024-06-15
Completion
2025-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB3616 Small molecule 180 mg Oral